Participants
| Role | Name | HCID | Charge |
|---|
| Reactant | Dibutylamine | HCID 8148 | — |
| Reactant | HCID 22914400 | HCID 22914400 | — |
| Solvent | Dimethylformamide | HCID 6228 | — |
| Product | HCID 22914563 | HCID 22914563 | 72% |
Reaction Steps
A solution of 278 mg (0.76 mmol) of 8-chloro-3-(5-chloromethyl-1,2,4-oxadiazol-3-yl)-5-methyl-5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepin-6-one in 5 ml of N,N-dimethylformamide was treated with 0.39 ml (2.3 mmol) of dibutylamine and stirred at room temperature under argon for 1.5 hrs. The solution was evaporated, the residue was dissolved in 20 ml of methylene chloride and the solution was washed three times with water. The organic phase was dried with sodium sulfate, filtered and evaporated. The crude product was chromatographed on 20 g of silica gel (methylene chloride/acetone 4:1). There were obtained 250 mg of 8-chloro-3-(5-dibutylaminomethyl-1,2,4-oxadiazol-3-yl)-5-methyl-5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepin-6-one, which was converted with ethereal hydrochloric acid into the hydrochloride. By crystallization from acetonitrile there were obtained 151 mg (39%) of 8-chloro-1-(5-dibutylaminomethyl-1,2,4-oxadiazol-3-yl)-5-methyl-5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepin-6-one hydrochloride (1:1.3) of m.p. 165°-175° (dec.).
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patent number | US05665718 |
|---|
| Source dataset | uspto-grants-1997_09 |
|---|
| ORD ID | ord-0de9e082a4b84603a5e11280b8f0ccfc |
|---|
| Source note | uspto-grants-1997_09 |
|---|